Combivir Conference Data

Medical Advocates
Zidovudine/Lamivudine (Combivir)

Conference Citations

15th CROI
4th IAS Conference
14th CROI
XVI International AIDS Conference
3rd IAS Conference
XV International AIDS Conference
11th CROI
2nd IAS Conference
XIV International AIDS Conference
9th CROI
1st IAS Conference

ZDV/3TC Main Page Main New/Newsworthy Home Page

Last updated: February 11, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

15th Conference on Retroviruses and Opportunistic
Infections

CONFERENCE PDF POSTER
Comparison of Adverse Fetal Outcomes in HIV-1-infected Antiretroviral-na�ve Pregnant Women
Who Have Received Combivir and Either Nevirapine or Nelfinavir for Prevention of Mother-to-Child
Transmission Antenatally
R Masaba, R Ndivo, I Nyangau, et al
PDF Poster Abstract

4th International AIDS Society (IAS) Conference on HIV
Pathogenesis, Treatment and Prevention

A randomized comparison of continued zidovudine plus lamivudine BID (Combivir, CBV) versus
switching to tenofovir DF plus emtricitabine (Truvada, TVD) each plus efavirenz (EFV) in
stable HIV infected persons: results of a planned 24 week analysis
Moyle G, Fisher M, Reilly G, and the SWEET Study Group
Abstract

Randomised comparative study of patients tolerance of and adherence to Combivir and tenofovir
versus stavudine lamivudine and tenofovir as HIV post- exposure prophylaxis(PEP)
Hawkins D, Higgs C, Mandalia S, et al
Abstract

Re-evaluation of occupational post exposure prophylaxis in resource-limited setting
Ifebuzor D., Ndubuka N , Ifebuzor, et al
Abstract

14th Conference on Retroviruses and Opportunistic
Infections

Addition of Short-course Combivir to Single-dose Nevirapine Reduces the Selection of
NPV-resistant HIV-1 with Infrequent Emergence of 3TC-resistant Variants
S Palmer, V Boltz, F Maldarelli, et al
Abstract

Emergence and Evolution of Drug Resistance in the Absence of Viral Load Monitoring during 48
Weeks of Combivir/Tenofovir within the DART Trial
D Pillay, C Kityo, V Robertson, et al
Abstract

XVI International AIDS Conference

Efficacy of Combivir + TDF as NRTI backbone in pretreated patients
S. Dupke, B. Hintsche, F. Schlote, T. Berg
Abstract
How to target TOPS: Combivir to reduce nevirapine-resistance after PMTCT:
a stochastic model
D. Westreich, A. Van Rie
Abstract

3rd International AIDS Society (IAS) Conference on HIV
Pathogenesis, Treatment and Prevention

Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention
of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent
development of maternal and paediatric NNRTI-resistant virus
McIntyre J.A, Martinson N., Gray G.E
Abstract

XV International AIDS Conference

Trizivir or Combivir plus Nevirapine as a simplified strategies in HIV-1 infected patients with viral
suppression. Results of 36 weeks of follow up of a randomized, multicenter open-label
simplification trial.SimplifiHAART Study
A Bonjoch, J Galvez, C Miralles, et al
Abstract
Addition of short course combivir (CBV) to single dose viramune (sdNVP) for prevention of
mother to child transmission (MTCT) of HIV-1 can significantly decrease the subsequent
development of maternal nnrti resistant virus
J McIntyre, N Martinson, V Boltz et al
Abstract
An observational cohort comparison of combivir plus either efavirenz, nevirapine, abacavir
or nelfinavir in african americans and hspanics with HIV infection
P Keiser, N Nassar, J B Yazdani, et al
Abstract

11th Conference on Retroviruses and Opportunistic
Infections

POSTER
Treatment Emergent Mutations for Previously Na�ve HIV-infected Adults Failing ZDV+3TC+EFZ
and ABC+3TC+EFV
D Irlbeck, E Rouse, S Castillo, et al.
PDF Poster       Abstract

POSTER
Determinants of Hyperlipidemia in ART-naive Subjects Treated with Trizivir, Combivir/Nelfinavir, or
Stavudine/Lamivudine
P Kumar, V Williams, K Tahima, et al
PDF Poster     Abstract

2nd IAS Conference on HIV and Pathogenesis

EFFECTIVENESS OF A SHORT COURSE OF ZIDOVUDINE + LAMIVUDINE AND PERIPARTUM
NEVIRAPINE TO PREVENT HIV-1 MOTHER-TO-CHILD TRANSMISSION. THE ANRS 1201
ITRAME-PLUS TRIAL, ABIDJAN, C�TE D�IVOIRE
F. Dabis, D.K. Ekou�vi, F. Rouet, et al
Abstract

PROSPECTIVE STUDY OF HYPERLIPIDEMIA IN ART-NAIVE SUBJECTS TAKING TRIZIVIR
(TZV), COMBIVIR (COM)/NELFINAVIR (NFV), OR STAVUDINE (D4T)/LAMIVUDINE (3TC)/NFV
P. Kumar, A. Rodriguez-French, M. Thompson, et al
Abstract

GENDER AND RACE SUBGROUP ANALYSES IN A PROSPECTIVE STUDY OF HYPERLIPIDEMIA
IN ART-NAIVE SUBJECTS TAKING TRIZIVIR (TZV), COMBIVIR (COM)/NELFINAVIR (NFV), OR
STAVUDINE (D4T)/LAMIVUDINE (3TC)/NFV
K. Tashima, P. Kumar, A. Rodriguez-French, et al
Abstract
LONG-TERM SAFETY AND EFFICACY OF TWO ANTIRETROVIRAL THERAPIES COMBIVIR+
ABACAVIR VERSUS COMBIVIR+NELFINAVIR-ECUREUIL 2- (CNAF3021)
S. Matheron, J.M. Livrozet, F. Boue, et al
Abstract

9th Conference on Retroviruses and Opportunistic Infections

CONFERENCE PDF POSTER
A Comparison of AZT/3TC vs 3TC/d4T and ddI/d4T in Combination with Efavirenz as First Line Therapy:
Efficacy and Safety Results after 48 Weeks
M. R. Domula, J. C. Wasmuth, A. J�tte, et al
PDF Poster        Abstract

XIV International AIDS Conference

Zidovudine and lamivudine (ZDV/3TC) seminal plasma:blood plasma (SP:BP) concentration
ratiosdo not predict total SP exposure
Y S Reddy, L Troiani, A Pereira, et al
Abstract

Adherence to AZT/3TC (Combivir) as post-exposure prophylaxis in
nonoccupational HIV exposures
A A Moe
Abstract

1ST IAS Conference on HIV and Pathogenesis

FINAL 12-MONTH RESULTS FROM THE COMBINE STUDY: A RANDOMIZED, OPEN,
MULTICENTER TRIAL COMPARING COMBIVIR PLUS NELFINAVIR OR NEVIRAPINE IN
NAIVE PATIENTS.
PODZAMCZER D, FERRER E, CONSIGLIO E, et al
Abstract

VIROLOGICAL RESPONSE IN RESERVOIRS IN HIV-INFECTED NAIVE PATIENTS
TREATED WITH COMBIVIR PLUS NELFINAVIR (CNF) OR NEVIRAPINE (CNR).
FERRER E, PODZAMCZER D, PEREZ P, PEREZ J, et al
Abstract

THE PI-SPARING COMPACT QUAD REGIMEN OF COMBIVIR (COM)/ABACAVIR
(ABC)/EFAVIRENZ (EFV) IS POTENT AND WELL-TOLERATED IN ANTIRETROVIRAL
THERAPY (ART) NA�VE SUBJECTS WITH HIGH VIRAL LOADS: 24-WK DATA
RUANE P, PARENTI D, HESSENTHALER S, SHEPP D, et al
Abstract

SAFETY AND EFFICACY OF MODIFYING ART BY SWITCHING FROM A PROTEASE
INHIBITOR(PI)- BASED REGIMEN TO EFAVIRENZ (EFV) PLUS COMBIVIR (CMB)
JOHNSON D, SQUIRES K
Abstract

METABOLIC AND ANTHROPOMETRIC CHANGES OBSERVED IN HIV-INFECTED PATIENTS
TREATED WITH COMBIVIR (ZDV/3TC) PLUS NELFINAVIR OR NEVIRAPINE (A SUBSTUDY OF THE
COMBINE-STUDY)
FISAC C, VIRGILI N, FERRER E, VILARASAU C, et al
Abstract

IMMUNE RESTORATION IN HIV+ NAIVE PATIENTS AFTER ONE YEAR OF COMBIVIR PLUS
NELFINAVIR OR NEVIRAPINE (SUBSTUDY OF THE COMBINE STUDY).
PLANA M, FERRER E, MART�NEZ C, PODZAMCZER D, et al
Abstract

ZDV/3TC Main Page Main New/Newsworthy Home Page

Combivir Conference Citations